AzTrials
AzTrials

Tracheostomy ComplicationCOVIDTrachNCT04572438

A Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy

An observational study of Tracheostomy Complication and Covid19, run by University College, London at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

COVIDTrach aims to assess the outcomes of tracheostomy in mechanically ventilated patients with COVID-19. The use of personal protective equipment and incidence of COVID-19 amongst operators is also recorded. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Tracheostomy
Type of treatment
Surgery or procedure
How many people
2,234 participants
Where
1 siteUnited Kingdom
Study dates
1 Aug 2020to 1 Oct 2021
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: Mechanically ventilated patients with COVID-19 who undergo tracheostomy in the UK.

Who may be able to join

  • Adult patients
  • Diagnosed with COVID-19
  • Mechanically ventilated
  • Undergoing elective surgical or percutaneous tracheostomy
  • Health care professionals involved in the tracheostomy procedure (main operator and assistant)

Who cannot join

  • COVID-19 patients undergoing an emergency tracheostomy;
  • Patients younger than 18 years of age

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • University College London NHS Foundation Trust

    London

Other trials in United Kingdom

About this study

Official title: COVIDTrach; a UK National Cohort Study of Mechanically Ventilated COVID-19 Patients Undergoing Tracheostomy

COVIDTrach aims to assess the outcomes of tracheostomy in mechanically ventilated patients with COVID-19. The use of personal protective equipment and incidence of COVID-19 amongst operators is also recorded.

Read the detailed description

COVID-19 can lead to a severe respiratory illness with 5-12% requiring mechanical ventilation.Standard UK intensive care practice is to consider a tracheostomy after 7-10 days of mechanical ventilation in order to facilitate weaning, reduce duration of mechanical ventilation, shorten intensive care stay and reduce complications relating to prolonged presence of an endotracheal tube. Given the severity of respiratory illness and a mortality in mechanically ventilated COVID 19 patients which exceeds 50%, the benefit of tracheostomy in this group is uncertain.

There are also unique considerations regarding health care professional (HCP) safety when performing tracheostomy in COVID-19 patients due to the potential of aerosol generation and transmission of the infection. ENT UK and other organisations have issued guidance regarding surgical tracheostomy in terms of timing, environment, technique and level of personal protective equipment (PPE). The ability of hospital departments to follow this guidance and the effectiveness of these measures is unknown.

This UK national cohort study aims to assess the effects of tracheostomy in mechanically ventilated COVID-19 patients in terms of the duration of mechanical ventilation, length of ICU and hospital stay and mortality. These data will be related to COVID-19 patients who are mechanically ventilated but do not undergo tracheostomy, as captured by the UK Intensive Care National Audit and Research Centre (ICNARC).

In parallel we will collect data on the tracheostomy procedure itself and compare these to national guidance on tracheostomy in patients diagnosed with COVID-19, and on COVID-19 infections in the surgical and medical teams involved in the tracheostomy procedure.

This proposal builds upon the ongoing COVIDTrach project that has captured data on 550 COVID-19 tracheostomies from 78 NHS hospitals throughout the UK so far. COVIDTrach has successfully brought together surgical, intensive care and anaesthetic specialists to capture early timepoints following tracheostomy. Moving forward, we will work with speech and language therapists and physiotherapists to capture later stages in the patient pathway. This will provide a unique and comprehensive assessment of the role of tracheostomy in COVID-19 patients. It will lay the foundation for further much needed multidisciplinary research into the role of tracheostomy in respiratory disease beyond the COVID-19 pandemic.

Being tested
Tracheostomy
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TracheostomyProcedure or surgery

    Tracheostomy is a procedure that creates a surgical airway in the windpipe to improve oxygenation of the lungs.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to wean

    Clinical outcome in terms of time in days from tracheostomy to successful weaning from mechanical ventilation.

    Measured: 12 months

Secondary outcomes (6)
  1. Airway related outcomes

    Clinical outcome in terms of length of time from tracheostomy to tracheostomy decannulation.

    Measured: 12 months

  2. Complications

    Clinical outcome in terms of tracheostomy related complications in terms of bleeding, displaced tube, blocked tube, other.

    Measured: 12 months

  3. Length of stay

    Clinical outcome in terms of length of stay at intensive care and total length of stay in hospital in days.

    Measured: 12 months

  4. Mortality

    Clinical outcomes in terms of patient mortality during or following tracheostomy, timing and cause of death

    Measured: 12 months

  5. Adherence of tracheostomy procedure to national guidance

    Following PPE guidance

    Measured: 12 months

  6. Operator wellness

    Symptomatic or test positive COVID-19 infection in healthcare professionals involved in the tracheostomy procedure.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2020
  2. Study start1 Aug 2020
  3. Primary completion1 Oct 2021
  4. Study completion1 Oct 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
2,234 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04572438
Sponsor's protocol ID
Z6364106/0000/00/00
Acronym
COVIDTrach
Status last verified
May 2022
First submitted
29 Sep 2020
Last updated
18 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • COVIDTrach collaborative. COVIDTrach: a prospective cohort study of mechanically ventilated patients with COVID-19 undergoing tracheostomy in the UK. BMJ Surg Interv Health Technol. 2021 Jul;3(1):e000077. doi: 10.1136/bmjsit-2020-000077. Epub 2021 Jul 8.

    PubMed 34282409

Questions about this trial

What is this clinical trial studying?

An observational study of Tracheostomy Complication and Covid19, run by University College, London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to wean (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04572438, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in